Benchmarking study 2021
19 agosto 2022 – In 2022, the pharmaceutical industry and Swissmedic conducted their ninth joint benchmarking study on approval times for human medicines. The comparison of the approval times of the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and Swissmedic directly shows the performance of Swissmedic as a small, independent national authorisation in relation to that of large, international reference authorities. It reveals that the Swissmedic authorisation time for new active substances is shorter than that of the EMA for the first time.
For more information, see here.